A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes....

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Cancer medicine (Malden, MA) Ročník 10; číslo 14; s. 4823 - 4831
Hlavní autori:	Oswald, Laura B., Arredondo, Brandy, Kadono, Mika, Martinez‐Tyson, Dinorah, Meade, Cathy D., Penedo, Frank, Antoni, Michael H., Soliman, Hatem, Costa, Ricardo L. B., Jim, Heather S. L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States John Wiley & Sons, Inc 01.07.2021 John Wiley and Sons Inc Wiley
Predmet:	Adult Advanced practice nurses Aged Breast cancer breast neoplasms Breast Neoplasms - chemistry Breast Neoplasms - drug therapy Breast Neoplasms - pathology Breast Neoplasms - psychology Cancer therapies Clinical Cancer Research Clinical trials Cyclin-dependent kinase 4 Cyclin-Dependent Kinase 4 - antagonists & inhibitors Cyclin-Dependent Kinase 6 - antagonists & inhibitors Cyclin-Dependent Kinase Inhibitor Proteins - adverse effects Cyclin-Dependent Kinase Inhibitor Proteins - therapeutic use Cyclin-dependent kinases Demographics Endocrine therapy Enzyme inhibitors Ethnicity Fatigue - chemically induced Female Hispanic Americans Humans Medical prognosis Metastases Metastasis Middle Aged Mixed methods research Molecular Targeted Therapy Needs Assessment neoplasm metastasis Oncologists Oncology Original Research Patient Reported Outcome Measures Patients patient‐reported outcomes measures psycho‐oncology Qualitative Research Quality of Life Symptom management patient-reported outcomes measures neoplasm metastasis qualitative research quality of life breast neoplasms psycho-oncology
ISSN:	2045-7634, 2045-7634
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Popis
Shrnutí:	Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes. This study is the first to describe CDK4/6 inhibitor symptoms from the lived perspectives of MBC patients taking CDK4/6 inhibitors and healthcare providers involved in MBC care. This study also explored patients’ symptom management and HRQOL concerns, and gathered feedback about developing supportive interventions for MBC. Methods MBC patients taking CDK4/6 inhibitors (N = 20) and MBC healthcare providers (N = 12) participated in semi‐structured interviews that were analyzed for qualitative themes. MBC patients completed surveys about HRQOL, symptoms, and unmet needs. Results Patient and provider perceptions of CDK4/6 inhibitor symptoms did not align with patients perceiving symptoms as more burdensome. Patients reported that supportive resources (e.g., support groups, blogs) that are not specific to MBC do not adequately meet their needs. Patients and providers were enthusiastic about developing supportive interventions specifically for MBC and offered considerations for designing such interventions. Conclusions Findings highlight differences in perceptions of CDK4/6 inhibitor symptom burden between MBC patients and providers. Results will inform the development of supportive interventions to assist MBC patients in managing CDK4/6 inhibitor symptom burden and maintaining HRQOL. Such interventions could also improve treatment outcomes. Metastatic breast cancer (MBC) patient and provider perceptions of symptoms associated with CDK4/6 inhibitor did not align, with patients perceiving symptoms as more burdensome. Patients reported that supportive resources (e.g., support groups, blogs) that are not specific to MBC do not adequately meet their needs, however patients and providers were enthusiastic about developing supportive interventions specifically for MBC and offered considerations for designing such interventions. Results will inform the development of supportive interventions to assist MBC patients in managing CDK4/6 inhibitor symptom burden and maintaining health‐related quality of life.
Bibliografia:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ISSN:	2045-7634 2045-7634
DOI:	10.1002/cam4.4055